European Nitrosamine Regulatory Actions
There is serious workload expected from all marketing authorisation holders (MAH) in EU! Let’s see what is expected for MAH compliance related to nitrosamines. On 26 September 2019, the EMA
PHARMA COLLOQUIUM 2020
PHARMA COLLOQUIUM 2020 is an arena for interdisciplinary exchange among professionals in the fields of pharmaceutical technology and its related aspects. Pharma Colloquium 2020 incorporates about each stage of information,
Pharmacovigilance World 2020
The Pharmacovigilance World 2020 conference will provide a platform for the participants to discuss, share and stay updated with present state of affairs in Pharmacovigilance and Drug safety, and contribute
4th Annual Digi-Tech Pharma & AI Conference
The 4th Annual Digi-Tech Pharma & AI 2020 conference brings with it even more interactive sessions, expert speakers, senior professionals and decision makers from leading pharma, bio-tech and healthcare industry. Meet the
4th Annual Global Clinical Trials Connect 2020
The 4th Annual Global Clinical Trials Connect 2020 will provide a platform to discuss on the futuristic advancements in clinical trials and clinical research. This multidisciplinary program involves broad participation of people from clinical
Traditional Medicine 2020
Traditional Medicine-2020 will follow the very best features of 2019 includes Plenary and Keynote lectures by eminent from around the world in addition to contribute papers both oral and poster presentations
Pharma Supply Chain & Security World 2020
The Annual Pharma Supply Chain and Security World Summit is back in London for the 3rd time, and this time with more focus on optimizing your supply chain challenges to ensure an
Biological and Biosimilar Medicinal Products
What is a biological medicinal product? A biological medicinal product is a medicinal product that contains an active substance produced or excreted from biological sources (human, animal, or microbiological). Due
Update about ANVISA´s role in pharmaceutical patent applications
In August 2017, the Brazilian Health Surveillance Agency (ANVISA) published Resolution No. 168/2017, which establishes the administrative procedures related to ANVISA´s “prior consent” for the granting of pharmaceutical patent applications,
Are You Free to Price Pharmaceuticals Products in South America?
On average, big pharmaceutical companies spend around 20% of their budget in research and development of new drugs. For smaller companies, the effort can be even higher, up to 50%